The possibility that angiotensin II (ANG II) exerts its effects through the activation of neutral sphingomyelinase (nSMase) has not been tested in kidneys. The results of the present study provide evidence for the activity and expression of nSMase in rat kidneys. In isolated perfused rat kidney, ANG II-induced renal vasoconstriction was inhibited by GW4869, an inhibitor of nSMase. We used nSMase for investigating the signal transduction downstream of ceramide. nSMase constricted the renal vasculature. An inhibitor of ceramidase (CDase), N-oleoylethanolamine (OEA), enhanced either ANG II-or nSMase-induced renal vasoconstriction. To demonstrate the interaction between the nSMase and cytosolic phospholipase A 2 (cPLA2) signal transduction pathways, we evaluated the response to nSMase in the presence and absence of inhibitors of arachidonic acid (AA) metabolism: arachidonyl trifluoromethyl ketone (AACOCF3), an inhibitor of cPLA2; 5,8,11,14-eicosatetraynoic acid (ETYA), an inhibitor of all AA pathways; indomethacin, an inhibitor of cyclooxygenase (COX); furegrelate, a thromboxane A 2 (TxA2)-synthase inhibitor; and SQ29548, a TxA 2-receptor antagonist. In these experiments, the nSMase-induced renal vasoconstriction decreased. ANG II or nSMase was associated with an increase in the release of thromboxane B2 (TxB2) in the renal perfusate of isolated perfused rat kidney. In addition, the coexpression of the ceramide with cPLA2, was found in the smooth muscle layer of intrarenal vessels. Our results suggest that ANG II stimulates ceramide formation via the activation of nSMase; thus ceramide may indirectly regulate vasoactive processes that modulate the activity of cPLA2 and the release of TxA2. renal vasoconstriction; angiotensin II; sphingomyelinase; phospholipase A2; cyclooxygenase; thromboxane A2 SPHINGOLIPIDS ARE A FAMILY of lipids that play essential roles as structural cell membrane components and also serve as substrates for enzymes that generate second messengers involved in cell signaling. Thus sphingolipids can be hydrolyzed by sphingomyelinases (SMases) (43). SMases are divided into three major classes, alkaline, acid, and neutral, according to the optimal pH for their activity, primary structure, and localization (15). Acid and alkaline SMases contribute to the hydrolysis of sphingomyelin in the luminal border of cells, in the extracellular space, or in the endosomal system, whereas neutral SMase (nSMase) functions in the inner leaflet of the plasma membrane (32). SMases cleave the phosphodiester linkage of sphingomyelin to produce phosphocholine and ceramide.
renal vasoconstriction; angiotensin II; sphingomyelinase; phospholipase A2; cyclooxygenase; thromboxane A2 SPHINGOLIPIDS ARE A FAMILY of lipids that play essential roles as structural cell membrane components and also serve as substrates for enzymes that generate second messengers involved in cell signaling. Thus sphingolipids can be hydrolyzed by sphingomyelinases (SMases) (43). SMases are divided into three major classes, alkaline, acid, and neutral, according to the optimal pH for their activity, primary structure, and localization (15) . Acid and alkaline SMases contribute to the hydrolysis of sphingomyelin in the luminal border of cells, in the extracellular space, or in the endosomal system, whereas neutral SMase (nSMase) functions in the inner leaflet of the plasma membrane (32) . SMases cleave the phosphodiester linkage of sphingomyelin to produce phosphocholine and ceramide.
A recent study reported that increased levels of vascular ceramide lead to vasoconstriction due to increased thromboxane A 2 (TxA 2 ) release in the vessels of spontaneously hypertensive rats (SHR) (45) . Along the same lines, several studies indicated that the abnormal production of TxA 2 is linked to the pathophysiology of renal and ANG II-dependent hypertension (7, 26) . Interestingly, treatment with the ANG II type 1 (AT 1 ) receptor antagonist losartan has been shown to reduce vascular ceramide levels and prevent the SMase-induced contraction in isolated carotid arteries from SHR (45) . In addition, several studies have reported that an accumulation of a sphingolipid, ceramide, its metabolites, or a combination contributes to the pathogenesis of renal injury (4, 5, 53, 54) . Therefore, it is possible that the interaction among ANG II, ceramide, and TxA 2 plays important roles in maintaining renal function and systemic blood pressure.
In this regard, in blood vessels ANG II has also been reported to induce the activation of cPLA 2 , which is responsible for the release of arachidonic acid (AA) from cell membrane phospholipids. The released AA is metabolized by cyclooxygenase (COX) into prostaglandins and TxA 2 ; these products modulate the vasoconstrictor response to ANG II in both renal and peripheral circulation to promote the maintenance of systemic pressure (6, 20) . Interestingly, Huang et al. (16) suggested that cross talk may occur between the SMase and phospholipase A 2 (PLA 2 ) signal transduction pathways. Another study demonstrated that ceramide can interact directly with cPLA 2 via the CaLB domain and thereby serves as a membrane-docking device that facilitates the cPLA 2␣ action in renal mesangial cells (17) . Therefore, one could speculate that ANG II stimulates ceramide formation via the activation of SMases; thus ceramide may indirectly regulate vasoactive processes that modulate the activity of cPLA 2 in the kidney, and this mechanism may be important for the regulation of blood pressure, most likely by modulating vasoconstrictor responses. To test this hypothesis, we developed the following specific aims: 1) to verify the activity and expression of nSMase in the kidney, 2) to determine whether ANG IIinduced renal vasoconstriction depends on nSMase, 3) to evaluate the renal vascular response to SMase, and 4) to determine whether the SMase and cPLA 2 signal transduction pathways interact in isolated perfused rat kidneys.
MATERIALS AND METHODS

Materials
Amplex red, an nSMase antibody (sc-26215), ␤-actin, cPLA2 antibody (sc-376618), anti-␣-smooth muscle actin (␣-SM actin; sc-130616), donkey anti-goat IgG-TR, donkey anti-goat IgG-FITC, goat anti-mouse IgG-FITC, and goat anti-mouse IgG-TR were used (Santa Cruz Biotechnology, Santa Cruz, CA). Enhanced chemiluminescence detection solution was used (GE Healthcare, Pittsburgh, PA; Vectashield, Vector Laboratories). Horseradish peroxidase (HRP), choline oxidase, alkaline phosphatase, sphingomyelin, ANG II, GW4869, dithiothreitol (DTT), SMase (from B cereus), N-oleoylethanolamine (OEA), arachidonyl trifluoromethyl ketone (AACOCF 3), 5,8,11,14-eicosatetraynoic acid (ETYA), indomethacin, and a ceramide antibody were purchased from Sigma (St. Louis, MO). Dibromo-dodecenyl-methylsulfimide (DDMS), furegrelate, and SQ29548 were purchased from Cayman Chemical (Ann Arbor, MI).
Male Wistar rats (250 -320 g) were housed in institutional animal facilities with free access to food and water. All studies were performed in accordance with the Mexican Federal Regulation for Animal Experimentation and Care (NOM-062-ZOO-1999, published in 2001) and approved by the Bioethics and Investigation Committees of Instituto Nacional de Cardiologia I. Ch.
SMase Activity
nSMase activity was estimated as described previously by Walters and Wrenn (48) . The reaction mixture contained the following components in a total volume of 200 l: 25 g renal homogenate proteins in 100 mM Tris·HCl, pH 7.4, 10 mM MgCl 2, 100 M Amplex red, 2 U/ml HRP, 0.2 U/ml choline oxidase, 8 U/ml alkaline phosphatase, and 500 M sphingomyelin. The reaction mixture was incubated at 37°C for 30 min. Fluorescence was measured using a microplate reader (Laurier Research Instrumentation, Otego, NY) with excitation at 545 nm and emission at 590 nm.
Western Blotting to Detect nSMase
Forty micrograms of protein was separated by SDS-PAGE on a 12% polyacrylamide gel and transferred onto a nitrocellulose membrane. Then, the membrane was washed and probed using a polyclonal antibody against nSMase (1:1,000) and donkey anti-goat IgG-HRP (1:1,000). Finally, enhanced chemiluminescence detection solution was added, and the membrane was exposed to Kodak Omat film.
Each membrane was stripped of bound antibody and reprobed with anti-␤-actin on the same membrane for quantitative comparison.
Preparation of Isolated Perfused Rat Kidney
Rats were anesthetized using pentobarbital sodium (45 mg/kg ip), and the right renal artery was cannulated using a 19-gauge needle. The kidney was removed and placed in a water-jacketed chamber maintained at 37°C (Langendorff preparation) (2, 3). The kidney was then perfused with Krebs-Henseleit solution under constant flow (6 ml/ min) without recirculation using an infusion pump (SC-Q 403U/VM4, Watson-Marlow, Wilmington, MA) to obtain a basal perfusion pressure of 100 mmHg. The Krebs-Henseleit solution (pH 7.4, 37°C) contained the following components: 118.5 mmol/l NaCl, 4.8 mmol/l KCI, 2.5 mmol/l CaCl 2, 1.2 mmol/l MgSO4, 1.2 mmol/l KH2PO4, 25 mmol/l NaHCO3, 5 mmol/l glucose, and 0.25% BSA. The perfusion pressure was continuously monitored using a pressure transducer (model PT300, Grass Instruments, West Warwick, RI) and recorded on a polygraph (model 7D, Grass Instruments, Quincy, MA). Because the flow was maintained at a constant rate, changes in the perfusion pressure were used as an index of changes in the resistance of the renal vasculature. A decrease in perfusion pressure indicated vasodilatation, whereas an increase in perfusion pressure indicated vasoconstriction. The responses are expressed as absolute changes (⌬) in perfusion pressure (in mmHg) from basal pressure.
Experimental Protocol
The following seven series of experiments was performed in the isolated perfused rat kidney. Protocol 1. To evaluate whether ANG II induces SMase activity, experiments were conducted in the presence and absence of GW4869 (10 mM), an inhibitor of nSMase, or DTT (1 mM), an inhibitor of aSMase. The inhibitors were added to the perfusing Krebs-Henseleit solution 30 min before the administration of ANG II (28, 31) . ANG II was administered as random bolus doses (1, 2, 4, 8, and 16 ng) that were added to the perfusate line just proximal to the kidney. Protocol 2. We used exogenous nSMase as a tool for investigating the signal transduction that is downstream of ceramide. nSMase (0.4 U) was administered as a bolus injection into the perfusate line of the isolated rat kidneys (36) . To further examine whether the enzymatic action of nSMase is essential for the regulation of renal vascular tone, we also examined the effects of heat-inactivated nSMase (56°C for 30 min) on isolated perfused rat kidneys.
Protocol 3. To examine the possibility that ceramide may cause vasoconstriction through intracellular conversion into sphingosine, we evaluated the response to either ANG II (4 ng) or nSMase (0.4 U) in the presence and absence of OEA, an inhibitor of ceramidase (10 Ϫ4 mM). OEA was added to the perfusing Krebs-Henseleit solution 30 min before the evaluation of the response to either ANG II or nSMase (22) .
Protocol 4. To demonstrate that nSMase catalyzes the hydrolysis of sphingolipids to release ceramide, which can interact with cPLA2␣ to generate AA and eicosanoids, we evaluated the response to nSMase (0.4 U) in the presence and absence of AACOCF3 (1 M), an inhibitor of cPLA 2␣; ETYA (1 M), an inhibitor of all AA pathways; DDMS (10 M), a selective inhibitor of the formation of 20-hydroxyeicosatrienoic acid (20-HETE); indomethacin, an inhibitor of COX (10 Ϫ5 M); furegrelate, a TxA 2-synthase inhibitor (10 Ϫ5 M); and SQ29548, a TxA2 receptor antagonist (10 Ϫ6 M). The inhibitors were added to the perfusing KrebsHenseleit solution 30 min before the administration of nSMase. Additionally, we evaluated the response to ANG II (4 ng) in the presence and absence of AACOCF3 or SQ29548 (1, 24, 40) .
Protocol 5. To evaluate the response to a small dose of ANG II in the presence of GW4869 (10 mM), AACOCF3, ETYA, indomethacin, and furegrelate, the inhibitors were added to the Krebs-Henseleit solution 30 min before the administration of ANG II (10 Ϫ10 M). ANG II was added to the Krebs-Henseleit solution and was infused for 30 min, and the response was measured for time.
Protocol 6. To evaluate whether other agonists produce vasoconstriction via the nSMase/ceramide/TxA2 pathway, we evaluated the vascular reactivity to a continuous infusion of either ET-1 or NE in isolated perfused rat kidneys in presence of GW4869, this was added to the Krebs-Henseleit solution for 30 min before and 30 min after the beginning of an infusion of either norepinephrine (NE) or endothelin (ET-1; 10 Ϫ10 M). Protocol 7: release of TxA2 in isolated perfused rat kidney. The short half-life of TxA2 impedes its measurement at physiological concentrations. Consequently, the measurement of TxB2, which has a half-life of 20 -30 min, is accepted as an indicator of TxA2 production. Thus, after a bolus injection of either ANG II (4 ng) or nSMase (0.4 U), the renal perfusate was collected over 5 min; during this time, the response to either ANG II or nSMase (0.4 U) was increasing and reaching the maximum renal vasoconstriction. The samples were stored at Ϫ20°C, and TxB 2 was measured using a specific enzymatic immunoassay kit (Cayman Chemical) according to the manufacturer's instructions. The levels of TxB2 are expressed in picograms per milliliter (pg/ml) (33) .
Immunofluorescence and Confocal Microscopy
After the stimulation with ANG II, the kidneys were used for immunofluorescence. The kidney sections were incubated with 10% blocking serum in PBS for 1 h at room temperature. After blocking, the tissue slices were incubated at 4°C overnight with the following primary antibodies (1:500): nSMase, neutral ceramidase (CDase), ceramide, or cPLA 2. After incubation, the sections were washed and incubated with the secondary antibody (donkey anti-goat IgG-FITC, goat anti-mouse IgG-FITC) for 4 h at room temperature.
The tissues were costained with anti-␣-SM mouse antibody to confirm that the nSMase, nCDase, ceramide, or cPLA 2 was expressed in the vascular smooth muscle cells. Negative controls were run using an identical protocol but excluding the primary antibody. For the dual immunostaining of the ceramide with cPLA 2, the sections was processed as described above. After incubation, the sections were washed and incubated with the secondary antibody (donkey anti-goat IgG-FITC, donkey anti-goat IgG-TR, goat anti-mouse IgG-FITC, and goat anti-mouse IgG-TR) for 4 h at room temperature. The tissues were mounted on microscope coverslips using Vectashield. Signals were examined under an FV1000 Confocal Laser Scanning Biological Microscope. Image analysis was performed using ImageJ software (Image J 1.36b, National Institutes of Health).
Statistical Analysis
Data are presented as means Ϯ SE. Student's t-test or one-way ANOVA with Bonferroni's posttest for multiple comparisons was performed using GraphPad Prism version 3.00 for Windows (GraphPad Software, San Diego, CA). The null hypothesis was rejected when P Ͻ 0.05.
RESULTS
SMase Activity
Our aim was to first verify the activity and expression of nSMase in the kidney and then to evaluate whether nSMase can be stimulated by ANG II in an isolated perfused rat kidney. The enzymatic activity of nSMase was measured in the medulla and cortex of the rat kidney. The enzymatic activity in the medulla was higher than that in the cortex (Fig. 1) .
SMase Expression
Western blot analysis revealed that the expression of nSMase was significantly higher in the renal medulla than in the cortex (Fig. 2) .
Vascular Response to ANG II in Isolated Perfused Rat Kidney
When ANG II was administered as random bolus doses (1, 2, 4, 8, and 16 ng), the multiple doses of ANG II increased the renal perfusion pressure in a dose-dependent manner in the isolated perfused rat kidneys, and for every dose, the responses were transient and not sustained; therefore, the response time was different. Interestingly, the ANG II-induced renal vasoconstriction was inhibited by GW4869. Furthermore, the use of DTT did not alter the effect of ANG II on isolated perfused rat kidneys (Fig. 3) . In addition, GW4869 alone did not change the basal perfusion pressure remained at a steady level (100 -110 mmHg).
Vascular Response to SMase in Isolated Perfused Rat Kidney
In this study, we used exogenous nSMase as a tool for investigating the signal transduction that is downstream of ceramide. A bolus injection of nSMase (0.4 U) increased the renal perfusion pressure by 30 Ϯ 1.9 mmHg in the isolated perfused rat kidneys; the responses to the bolus injections were transient and not sustained (Fig. 4) . To further examine whether the enzymatic action of nSMase is essential for inducing renal vasoconstriction, we also examined the effects of heat-inactivated nSMase on isolated perfused rat kidney. Heatinactivated nSMase had no effect on rat vascular tone, indicating that the intact enzymatic action of nSMase is required for renal vasoconstriction.
Vascular Response to Either ANG II or SMase with Inhibition of Ceramidase in Isolated Perfused Rat Kidneys
To examine the possibility that ceramide may cause vasoconstriction through an intracellular conversion into sphingosine, we evaluated the response to either nSMase (0.4 U) or ANG II (4 ng) in the presence and absence of OEA, an inhibitor of ceramidase. The renal perfusion pressure from basal was not affected by OEA alone, but the inhibition of the ceramidase with OEA enhanced the nSMase-induced renal vasoconstriction (Fig. 4A ) and the ANG II-induced renal vasoconstriction (Fig. 4B) . Accordingly, we believe that in the isolated perfused rat kidney, the ceramide levels increase in response to nSMase and ANG II.
Interaction Between the SMase and cPLA 2 Signal Transduction Pathways in Isolated Perfused Rat Kidneys
To demonstrate that nSMase catalyzes the hydrolysis of sphingolipids to release ceramide, which interacts with cPLA 2␣ to generate AA and eicosanoids, we evaluated the response to nSMase in the presence and absence of AACOCF 3 , ETYA, DDMS, indomethacin, furegrelate, or SQ29548. The pretreatment with either AACOCF 3 or ETYA inhibited the nSMaseinduced renal vasoconstriction. DDMS did not affect the nSMase-induced renal vasoconstriction. These results suggest that the 20-HETE pathway cannot explain the nSMase-induced vasoconstriction in the isolated perfused rat kidney. The pretreatment with indomethacin decreased the nSMase-induced renal vasoconstriction; these results suggest that renal vasoconstriction depends on the COX pathway (Fig. 5A) . In light of the observation concerning indomethacin, we decided to investigate the role of TxA 2 as a potential mediator of the vasoconstriction. When we applied either furegrelate (a TxA 2 -synthase inhibitor) or SQ-29,548 (a TxA 2 receptor antagonist), both diminished the nSMase-induced renal vasoconstriction (Fig.  5A) . In addition, when we evaluated the response to ANG II in the presence and absence of AACOCF3, ETYA, indomethacin, and furegrelate, all diminished the ANG II-induced renal vasoconstriction (Figs. 5B) . In addition, infusion of ANG II (10 Ϫ10 M) increased perfusion pressure by 29 Ϯ 1.7 mmHg and was sustained. The presence of GW4869, AACOCF3, ETYA, indomethacin, or furegrelate in the perfusion solution reduced the maximal ANG II response by 60% (Fig. 6) . Our results suggest that either nSMase or ANG II stimulates TxA 2 synthesis in renal tissues.
To test whether other agonists produce vasoconstriction via the nSMase/ceramide/TxA 2 pathway, we evaluated the vascular reactivity to a continuous infusion of either ET-1 or NE in isolated perfused rat kidneys in the presence of GW4869. ET-1 and NE increased perfusion pressure by 38 Ϯ 3 mmHg (P Ͻ 0.01) and 31 Ϯ 4 mmHg (P Ͻ 0.01), respectively. The renal vascular reactivity to either ET-1 or NE was not attenuated by GW4869. These results showed that ET-1 and NE are not associated with the activation of nSMase in the renal vasculature.
TxB 2 Production in Isolated Perfused Rat Kidneys in Response to Either ANG II or nSMase
To demonstrate that either ANG II or nSMase stimulates TxA 2 synthesis in kidneys, we measured TxB 2 production in isolated perfused rat kidneys in response to either ANG II or nSMase. The bolus injection of either nSMase (0.4 U) or ANG II (4 ng) was also associated with an increase in the release of TxB 2 , the TxA 2 metabolite; TxB 2 production was inhibited by furegrelate (Fig. 7) .
Immunofluorescence Using Confocal Microscopy
After the stimulation with ANG II, the kidneys were used for immunofluorescence.
Representative images show the immunofluorescence staining for nSMase, nCDase, ceramide, cPLA 2 (yellow or orange) expression Figure 9C also shows a section from a kidney doubly labeled with ceramide and cPLA 2 ; coexpression also can be observed in the intrarenal vessels. (Figs. 8 and 9 ).
DISCUSSION
In the present study, our results provide evidence of the activity and expression of nSMase in rat kidneys. Interestingly, it has been reported that treatment with the AT 1 receptor antagonist losartan reduces vascular ceramide levels and prevents SMase-induced contraction in isolated carotid arteries from SHR (47) . However, the possibility that ANG II exerts some of its effects through the activation of nSMase has not been determined in the vasculature. When we evaluated the response to ANG II in isolated perfused rat kidneys, we found that the ANG II-induced renal vasoconstriction was inhibited by GW4869. These results suggest that ANG II stimulates ceramide formation via the activation of nSMase. In addition, when we evaluated the response to exogenous nSMase in isolated perfused rat kidneys, we found that it induced renal vasoconstriction. Therefore, it is possible that ceramide may regulate renal vasoconstriction.
This observation is consistent with studies that demonstrated that treatment with ceramide and/or SMase leads to contraction in isolated vessels (28, 36, 55, 56) . In contrast, other studies have shown that ceramide induces vasorelaxation (endothelium dependent and endothelium independent) (10, 21-23, 32) . The reason for this discrepancy is unknown. In this study, it was not possible to evaluate the renal vascular response to exogenous ceramide because ceramide is not soluble in Krebs-Henseleit solution.
However, it is also important to consider whether ceramide can be converted to sphingosine by CDase (47a). In this regard, several studies have demonstrated that sphingosine elicited vasoconstriction in coronary arteries and caused relaxation in aortic rings as well as in pulmonary artery rings (17, 36) . In addition, it has been reported that OEA is a potent inhibitor of CDase in the kidney (34, 47a) . In this study, we also demonstrate the expression of CDase in intrarenal vessels. Therefore, to investigate the role of sphingolipid metabolites, especially sphingosine, in mediating vasoconstriction, we utilized an inhibitor of CDase, OEA. In these experiments, we observed that either ANG II-induced renal vasoconstriction or nSMaseinduced renal vasoconstriction was enhanced in the presence of OEA; these results suggest that the inhibition of CDase produces an accumulation of ceramide in isolated perfused rat kidneys. Therefore, sphingosine is not involved in the renal vasoconstriction stimulated by either ANG II or nSMase. However, it has been reported that OEA causes vasorelaxation partly via an endothelium-dependent mechanism (14) . More recently, attention has turned to a possible role of COX metabolites in the OEA actions in the vasculature (49) .
Interestingly, a recent study reported that the SMase-induced ceramide increase in the carotid artery of SHR leads to vasoconstriction via a PLA 2 , COX-1, and thromboxane synthasedependent mechanism (46) . On the other hand, it has been reported that ceramide can interact directly with cPLA 2 via the CaLB domain and thereby serves as a membrane-docking device that facilitates the cPLA 2␣ action in renal mesangial cells (19) . To clarify the possible involvement of cPLA 2 activation in SMase-induced renal vasoconstriction, we tested the effect of AACOCF 3 , an inhibitor of cPLA 2␣ . Our data show that the presence of AACOCF 3 diminished either the SMaseinduced renal vasoconstriction or the ANG II-induced renal vasoconstriction by ϳ50%. Interestingly, Leis et al. (27) reported that AACOCF 3 is also a potent inhibitor of COXs. This observation and our results suggest that ceramide can regulate the production of eicosanoids. To determine whether the SMase-induced renal vasoconstriction depends on AA metabolism, we tested the effects of ETYA, an inhibitor of all AA pathways, DDMS, a selective inhibitor of the formation of 20-HETE, and indomethacin, an inhibitor of COX. We observed that ETYA and indomethacin diminished the SMaseinduced renal vasoconstriction. Accordingly, we believe that the ANG II/nSMase/ceramide-PLA 2 pathway liberates AA, and free AA serves as a substrate for the COX pathway. COX converts AA to prostaglandin endoperoxide H 2 (PGH 2 ), the precursor of the prostaglandins (PGE 2 , PGI 2 ) and the prostanoids (TxA 2 ). In this regard, it has been reported that the prostaglandins PGE 2 and PGI 2 play a critical role in buffering ANG II-mediated constriction (41) . In addition, it has been reported that COX inhibition usually potentiates the vasoconstrictor actions of pressor hormones by removing the modulatory influence of PGE 2 and/or PGI 2 (11) . In the present study, the indomethacin treatment did not potentiate the nSMaseinduced renal vasoconstriction. Therefore, indomethacin decreases nSMase-induced renal vasoconstriction by abolition of the release of vasoconstrictor prostanoids, TxA 2 and/or PGH 2 . However, a recent study reported that indomethacin inhibits endothelial nitric oxide synthase (eNOS) activity (37) .
On the other hand, it has been reported that TxA 2 is a major product of AA metabolism via the COX pathway and is produced in small quantities by the kidney. Functionally, TxA 2 acts on the TP receptor (TxA 2 receptor) to induce smoothmuscle contraction (40) . Therefore, to determine whether TxA 2 is involved in SMase-induced renal vasoconstriction, we tested the effects of either furegrelate (an inhibitor of thromboxane synthase) or SQ29548 (a TxA 2 receptor antagonist). Both furegrelate and SQ29548 pretreatment decreased the SMaseinduced renal vasoconstriction. When we evaluated the response to ANG II, the presence of either furegrelate or SQ29548 diminished the ANG II-induced renal vasoconstriction. In addition, furegrelate decreased the production of TxA 2 in isolated perfused rat kidneys in response to either ANG II or nSMase. These results showed that either the SMase-induced renal vasoconstriction or the ANG II-induced renal vasoconstriction involves the production of TxA 2 . In this regard, other studies have also reported that TxA 2 is synthesized in the kidney in response to ANG II (12, 39, 50, 51) .
Nevertheless, it is important to note that the ceramide/TxA 2 pathway contributes 50% of the renal vasoconstriction produced by either nSMase or ANG II; therefore, our results suggest that other mechanisms can explain the renal vasoconstriction produced by either nSMase or ANG II/AT 1 /nSMase. With respect to this possibility, it has been reported that the activation of nSMase leads to the generation of ceramide, which, in turn, may activate other proteins, such as PKC, K V channels, Rho-kinase, voltage-independent Ca 2ϩ channels, protein phosphatase 2A (PP2A), or NADPH oxidase (9, 28, 45, 56 -58 sensitization in the contractile proteins, thus inhibiting the dephosphorylation of MLC phosphatase (MLCP) and maintaining force generation. In cases in which NO production is significantly decreased and/or reactive oxygen species (ROS) levels are increased, the activation of RhoA/Rho-kinase may contribute to increased vascular tone (29, 30, 52) . Furthermore, Src-dependent pathways and nicotinic acid adenine dinucleotide phosphate (NAADP), another second messenger generated by the enzyme ADP-ribosyl (ADPR) cyclase, may contribute to the Ca 2ϩ signaling of ANG II (8, 13, 14, 29, 30) . Furthermore, to support the hypothesis that the ANG II/AT 1 receptor/nSMase/ceramide-PLA 2 /TxA 2 pathway contributes to the regulation of renal vasoconstriction, we demonstrated the expression of nSMase, ceramide, and cPLA 2 in the smooth muscle layer of intrarenal vessels. Accordingly, we believe that AT 1 receptor and nSMase, as well as ceramide and cPLA 2 , may interact in the kidney.
Recent studies have indicated that other vasoconstrictor peptides, such as ET-1, and vasodilator peptides, such as bradykinin (BK), activate nSMase. In this regard, it has been reported that ET-1 stimulates nSMase activity through a p38MAPK-dependent pathway, leading to vascular cell adhesion molecule (VCAM-1) expression (38) . The activation of the BK-B 1 receptor leads to the activation of SMase, and the generated ceramide induces vasodilatation in rat mesenteric small arteries (25) . In this regard, we also found that the activation of the BK-B 1 receptor produced vasodilation in isolated perfused kidneys (3) .
Interestingly, the pathophysiological actions of ANG II are mediated by G protein-coupled receptors; therefore, it is possible that other constrictor agonists (e.g., ET-1, NE) could induce renal vasoconstriction through the nSMase/ceramide/ TxA 2 pathway. In this study, to test whether other agonists produce vasoconstriction via the nSMase/ceramide/TxA 2 pathway, we evaluated the vascular reactivity to a continuous infusion of either ET-1 or NE in isolated perfused rat kidneys. Our results indicate that the renal vascular reactivity to either ET-1 or NE was not attenuated by GW4869. These results showed that ET-1 and NE are not associated with the activation of nSMase in the renal vasculature. Additional studies are required to determine whether other agonists produce vasoconstriction via the nSMase/ceramide/TxA 2 pathway.
In summary, this study shows that ANG II stimulates ceramide formation via the activation of nSMase, and thus the study shows that ceramide may indirectly regulate vasoactive processes that modulate the activity of cPLA 2 and release TxA 2 in isolated perfused rat kidneys (Fig. 10) . Thus the activation of SMase by ANG II may contribute to the development of vascular dysfunction; therefore, nSMase inhibitors could be tools for the treatment of renal diseases.
